找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Resistance to Proteasome Inhibitors in Cancer; Molecular Mechanisms Q. Ping Dou Book 2014 Springer International Publishing Switzerland 201

[復(fù)制鏈接]
查看: 40302|回復(fù): 56
樓主
發(fā)表于 2025-3-21 17:14:32 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer
副標(biāo)題Molecular Mechanisms
編輯Q. Ping Dou
視頻videohttp://file.papertrans.cn/829/828458/828458.mp4
概述Reveals latest discoveries related to the molecular mechanisms of proteasome inhibitor resistance.Discusses proteasome inhibitor resistance in multiple contexts, including multiple myeloma, leukemia,
叢書(shū)名稱Resistance to Targeted Anti-Cancer Therapeutics
圖書(shū)封面Titlebook: Resistance to Proteasome Inhibitors in Cancer; Molecular Mechanisms Q. Ping Dou Book 2014 Springer International Publishing Switzerland 201
描述.The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume..This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies..
出版日期Book 2014
關(guān)鍵詞20S proteasome inhibitors; bortezomib; carfizomib; leukemia; multiple myeloma; ubiquitin-proteasome pathw
版次1
doihttps://doi.org/10.1007/978-3-319-06752-0
isbn_softcover978-3-319-37703-2
isbn_ebook978-3-319-06752-0Series ISSN 2196-5501 Series E-ISSN 2196-551X
issn_series 2196-5501
copyrightSpringer International Publishing Switzerland 2014
The information of publication is updating

書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer影響因子(影響力)




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer影響因子(影響力)學(xué)科排名




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer被引頻次




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer被引頻次學(xué)科排名




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer年度引用




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer年度引用學(xué)科排名




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer讀者反饋




書(shū)目名稱Resistance to Proteasome Inhibitors in Cancer讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 22:55:29 | 只看該作者
Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resiercome resistance, e.g., by novel proteasome inhibitors and combinations of bortezomib with other chemotherapeutic drugs. Finally, an update is provided of the ongoing clinical trials investigating the potential benefits of proteasome inhibitors in acute leukemia.
板凳
發(fā)表于 2025-3-22 01:27:47 | 只看該作者
地板
發(fā)表于 2025-3-22 07:01:42 | 只看該作者
Resistance to Proteasome Inhibitors in Multiple Myeloma, bone destruction, anemia, hypercalcemia, and renal failure. Although MM remains incurable, a dramatic paradigm shift in the treatment of MM has occurred over the past decade through the introduction of novel agents, including the development of small molecule inhibitors targeting the proteasome. Am
5#
發(fā)表于 2025-3-22 09:43:59 | 只看該作者
6#
發(fā)表于 2025-3-22 15:35:09 | 只看該作者
7#
發(fā)表于 2025-3-22 21:06:12 | 只看該作者
8#
發(fā)表于 2025-3-22 21:57:33 | 只看該作者
9#
發(fā)表于 2025-3-23 04:51:34 | 只看該作者
10#
發(fā)表于 2025-3-23 06:16:15 | 只看該作者
Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and Newthe in vitro sensitivity of HNSCC cells to proteasome inhibitors, clinical testing of bortezomib in HNSCC patients has encountered obstacles of inherent resistance and adverse toxicities. To combat these difficulties, current efforts are focused on developing strategies that co-target the proteasome
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 09:19
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
临潭县| 乡宁县| 芮城县| 依安县| 上虞市| 抚宁县| 壤塘县| 泸州市| 娄烦县| 合作市| 沙河市| 瑞金市| 元阳县| 建湖县| 驻马店市| 广昌县| 福贡县| 古交市| 莱西市| 大埔县| 庆阳市| 麦盖提县| 巴青县| 金沙县| 邯郸县| 临澧县| 迁安市| 溧阳市| 平江县| 海南省| 菏泽市| 昭平县| 小金县| 诸城市| 潢川县| 南漳县| 平遥县| 繁峙县| 黔南| 鄯善县| 墨玉县|